143 related articles for article (PubMed ID: 24295975)
1. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.
Xu B; Wang L; González-Molleda L; Wang Y; Xu J; Yuan Y
Antimicrob Agents Chemother; 2014; 58(1):563-73. PubMed ID: 24295975
[TBL] [Abstract][Full Text] [Related]
2. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.
González-Molleda L; Wang Y; Yuan Y
Antimicrob Agents Chemother; 2012 Feb; 56(2):893-902. PubMed ID: 22106228
[TBL] [Abstract][Full Text] [Related]
3. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
4. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
J Virol; 2017 May; 91(10):. PubMed ID: 28275189
[TBL] [Abstract][Full Text] [Related]
5. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
[TBL] [Abstract][Full Text] [Related]
6. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
Watanabe T; Fujimuro M
Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
[TBL] [Abstract][Full Text] [Related]
7. Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.
Wang V; Davis DA; Deleage C; Brands C; Choi HS; Haque M; Yarchoan R
J Virol; 2020 Feb; 94(5):. PubMed ID: 31801863
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed inhibits Kaposi's sarcoma-associated herpesvirus replication through blocking dTMP synthesis.
Chen J; Zhang H; Chen X
Antiviral Res; 2020 Aug; 180():104825. PubMed ID: 32461120
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus.
Wu T; Wang Y; Yuan Y
Antiviral Res; 2014 Jul; 107():95-101. PubMed ID: 24821256
[TBL] [Abstract][Full Text] [Related]
10. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
12. Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication.
Park MK; Cho H; Roh SW; Kim SJ; Myoung J
Sci Rep; 2019 Feb; 9(1):2372. PubMed ID: 30787356
[TBL] [Abstract][Full Text] [Related]
13. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy.
Andrei G; Snoeck R
Curr Opin Infect Dis; 2015 Dec; 28(6):611-24. PubMed ID: 26524334
[TBL] [Abstract][Full Text] [Related]
15. Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.
Zhu W; Burnette A; Dorjsuren D; Roberts PE; Huleihel M; Shoemaker RH; Marquez VE; Agbaria R; Sei S
Antimicrob Agents Chemother; 2005 Dec; 49(12):4965-73. PubMed ID: 16304159
[TBL] [Abstract][Full Text] [Related]
16. The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication.
Uppal T; Meyer D; Agarwal A; Verma SC
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728255
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.
Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C
J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900
[TBL] [Abstract][Full Text] [Related]
18. The pleiotropic effects of Kaposi's sarcoma herpesvirus.
Schulz TF
J Pathol; 2006 Jan; 208(2):187-98. PubMed ID: 16362980
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.
Cheng F; He M; Jung JU; Lu C; Gao SJ
J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746
[TBL] [Abstract][Full Text] [Related]
20. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
